TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: QF muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Femoral cartilage thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kellgreen-Lawrence Radiological Stages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance and gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of ophthalmologic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of DM status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean change in amygdala volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean change in hippocampus volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean change in thalamus volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean change in Nucleus accumbens volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean change in amygdala activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean change in hippocampus activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: first need of opiate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Additional Anti-VEGF Injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain catastrophizing scale- situation specific
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharmacodynamics of rivaroxaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ASIA Impairment Scale (ASIA / AIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lower Extremity: 10 Meter Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline clinical markers associated with SPMS diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline MRI markers associated with SPMS diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alternative Complement Pathway Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in number of ventricular tachycardia (VT) episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Recruited
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants Completing 12 week Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Performing Physical Activity (PA) on 70% of assigned Videos
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total QRS complex count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of signal loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration time curve (AUC0-96)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average percent BOLD signal change during the 4-Choice Serial-Reaction Time Task (4-CSRTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average percent BOLD signal change during the Stop Signal Task (SST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average percent BOLD signal change during resting state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Assessment of brain perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients with intracerebral hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG alpha band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of complete biochemical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specific Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Abdominal Distension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fugl Meyer Assessment score (lower limbs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to RVU120 (anti-cancer activity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline TSPO uptake (SUV max) at 6 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Blood flow value (ml/g/min) at 6 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Increased Seizure Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Modification on ATEC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modification of ASRS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Balance assessment using mCTSIB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final angiographic minimal lumen diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pancreas related Quality of Life Index (PANQALI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Stoma complications
Endpoint domain: Adverse events/effects
Primary endpoint: Cellular and molecular composition of the tumour microenvironment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Major pathological response rates (MPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functionality of the IV SafeLock
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ejection fraction measured by 3-dimensional echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change scores of Five Times Sit to Stand Test (FTSST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change scores of Timed Up and Go Test (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change scores of 10-meter walk test (10MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoperative bleeding loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Binge Eating Disorder severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in lung injury grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Positive Mental Health Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Depression Anxiety Stress Scale 21
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical response mSWAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attention domain of Addenbrooke's Cognitive Examination-III
Endpoint domain: Cognitive functioning
Primary endpoint: Memory domain of Addenbrooke's Cognitive Examination-III
Endpoint domain: Cognitive functioning
Primary endpoint: Fluency domain of Addenbrooke's Cognitive Examination-III
Endpoint domain: Cognitive functioning
Primary endpoint: Language domain of Addenbrooke's Cognitive Examination-III
Endpoint domain: Cognitive functioning
Primary endpoint: Visuospatial domain of Addenbrooke's Cognitive Examination-III
Endpoint domain: Cognitive functioning
Primary endpoint: Changes in total body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rate of post operative ipsilateral stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neck Disability Assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lumbar spine lateral flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinical utility/effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness and cost-utility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Attending ≥80% of Intervention Sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Positive response rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Smoking status at 12 months post-enrollment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking status at 3 months post-enrollment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wear time compliance of Panoramic Bracelet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent time asleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite progression-free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in 24 hours ambulatory systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: prothrombin time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Pain Level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation of Study
Endpoint domain: Adverse events/effects
Primary endpoint: Objective neurocognitive functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serum p-Tau 217 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Serum Glial Fibrillary Acidic Protein (GFAP) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Serum Neurofilament Light Chain (NfL) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: occurrence of decompensation of cirrhosis or liver-related death
Endpoint domain: Mortality/survival
Primary endpoint: Changes in glutamate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of advanced adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Self-Care Heart Failure Index (SCHFI, v.7.2)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Minnesota Living with Heart Failure (MLHF) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: The EuroQoL-5D-5L instruments
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Validity of the Cumulative Life Course Impairment Instrument (DermCLCI-p)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reliability of the Cumulative Life Course Impairment Instrument (DermCLCI-p)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Responsiveness of the Cumulative Life Course Impairment Instrument (DermCLCI-p)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Willingness to vaccinate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of PEF treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Reading of skin reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Frequency of solicited or unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of patients who maintain both urinary continence and erectile potency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: proportion of patients free from treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirm mutations in the ABCA4 gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure BCVA and LLVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure the area of retinal atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thromboelastography parameter R value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in exercise stroke volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in exercise oxygen pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Clinician Administered PTSD Scale for DSM-5 (CAPS-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG activity during interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Satisfaction of intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Completion rate of study instrument
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Global Assessment of Functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Plasma SEPP1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Successful tracheal intubation on the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Anxiety rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sudden death within the first 12 months of BTKi therapy
Endpoint domain: Mortality/survival
Primary endpoint: arrhythmogenic cardiac effects of BTKi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment success for the treated seizure within 90 seconds after IMP administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Treatment success for the treated seizure with no recurrence up to 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Therapeutic efficacy in treating acute watery diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time required for absorption and distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with HIV viral suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma Control Test for Children
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of generalized, convulsive and prolonged seizures
Endpoint domain: Adverse events/effects
Primary endpoint: Quantify study withdrawal and patient/caregiver experience
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of induction of habitual seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Anxiety during the procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain as measured by the Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the score of Fugl-Meyer Assessment Scale of Upper-Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the score of Balance Subscale of the Fugl-Meyer Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak oxygen consumption (peak VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dosing limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative proportion of subjects who developed peptic ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of attempts required to obtain access
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time for the access
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence and nature of Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinical significance abnormal values in hematology parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with clinical significance abnormal values in biochemistry parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with significant changes in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle activity of the bilateral trapezius pars descendens muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Evolution of movement speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution of movement accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of [(14)C]ADC189 and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration [Cmax] of [(14)C]ADC189 and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole blood and serum concentrations of total radioactivity of [(14)C]ADC189
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of healed lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Recurrence-free survival probability
Endpoint domain: Mortality/survival
Primary endpoint: ROWE score composite
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Screened Participants with Hearing Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of the procedure without conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Verified chlorine usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood Phe concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the HIV RNA curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Young Mania Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Negative Symptom Scale (BNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Personal and Social Performance Scale (PSP) scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Scale of Unawareness of Mental Disorder (SUMD) scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Concentration of CD4+ T Helper (TH)17 cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: upper extremity spasticity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Fugl Meyer Upper Extremity Assessment Questionnaire wrist and hand assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: ABILHAND Stroke Hand Function Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of oral mucositis with grade ≥ 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who experience wearing-off effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with worsening ≥1 category for PROMIS physical health NRS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients with worsening ≥ 1 category for PROMIS mental health NRS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients with worsening ≥ 1 category for PROMIS fatigue NRS
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Proportion of patients with worsening ≥1 category for PROMIS pain NRS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain pre procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain post procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety pre procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety post procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fatty liver detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent difference in partial-thickness wound conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Neglect Score on Catherine Bergego Scale (CBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes